Suspension of trading

Business Segments MORPHOSYS Nasdaq

Stocks

Delayed Nasdaq 23:00:00 02/08/2024 +03			5-day change	1st Jan Change
18.96 ^USD	+2.43%		-.--%	-

Breakdown by Business Segment (EUR)

Fiscal Period: December	2019	2020	2021	2022	2023
Life Sciences Tools and Services
Partnered Discovery	37.47M	49.07M	-	-	-
Total Assets	22.93M	21.13M	-	-	-
CAPEX	-625K	-429K	-	-	-
EBT	-	37.42M	-	-	-
D&A	1.38M	1.1M	-	-	-
Operating Income	26.8M	37.42M	-	-	-
Biological Products
Proprietary Development	34.29M	279M	-	-	-
Total Assets	85.08M	242M	-	-	-
CAPEX	-2.83M	-48.26M	-	-	-
EBT	-	59.41M	-	-	-
D&A	1.72M	3.2M	-	-	-
Operating Income	-109M	13.47M	-	-	-
EBT	-	-702K	-	-	-
Operating Income	-25.72M	-32.94M	-	-	-
D&A	355K	425K	-	-	-
EBT	-	-73.64M	-	-	-
CAPEX	-207K	-526K	-	-	-
Total Assets	388M	1.4B	-	-	-

Geographical breakdown of sales (EUR)

Fiscal Period: December	2019	2020	2021	2022	2023
USA	-	-	-	-	211M
Total Assets	4.4M	8.3M	1.1B	1.17B	1.12B
CAPEX	-1.3M	-1.6M	-1.7M	-	-
Europe (Excluding Germany)	-	-	-	-	26.79M
Asia	-	-	-	-	8K
USA and Canada	32.29M	319M	156M	249M	-
Total Assets	12.5M	-	-	-	-
CAPEX	-100K	-100K	-	-	-
Germany	145K	-	-	-	-
Total Assets	176M	312M	133M	143M	90.6M
CAPEX	-2.3M	-47.6M	-24.5M	-15.2M	-2.9M
Europe and Asia	39.32M	8.64M	23.33M	29.34M	-